ADGM成立后，NeOnc科技完成对NuroMENA 5000万美元的基石投资

NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, announced today the official incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market (ADGM). With this regulatory milestone completed, all contingencies have now been met to finalize the previously announced $50 million cornerstone investment effort led by Quazar Investment into NuroMENA Holdings Ltd.

This strategic partnership will support the launch of NeOnc's innovative CNS platform across the MENA region and help to accelerate development of its therapeutic pipeline, including the NEO212 and NEO100 clinical programs.